Literature DB >> 32684856

How the CARD trial has changed the cards on the table for metastatic castration resistant prostate cancer.

Giandomenico Roviello1, Benedetta Panella1.   

Abstract

Entities:  

Year:  2020        PMID: 32684856      PMCID: PMC7352039          DOI: 10.1016/j.rpor.2020.04.009

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


× No keyword cloud information.
  5 in total

1.  Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

Authors:  Mario Eisenberger; Anne-Claire Hardy-Bessard; Choung Soo Kim; Lajos Géczi; Daniel Ford; Loïc Mourey; Joan Carles; Phillip Parente; Albert Font; Gabriel Kacso; Mustapha Chadjaa; Wenping Zhang; John Bernard; Johann de Bono
Journal:  J Clin Oncol       Date:  2017-08-15       Impact factor: 44.544

2.  Is there still a place for docetaxel rechallenge in prostate cancer?

Authors:  Roberto Petrioli; Edoardo Francini; Giandomenico Roviello
Journal:  World J Clin Oncol       Date:  2015-10-10

Review 3.  The third line of treatment for metastatic prostate cancer patients: Option or strategy?

Authors:  Giandomenico Roviello; Roberto Petrioli; Letizia Laera; Edoardo Francini
Journal:  Crit Rev Oncol Hematol       Date:  2015-05-21       Impact factor: 6.312

4.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

5.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.